BACKGROUND AND PURPOSE: Cloxyquin (5-cloroquinolin-8-ol) has been described as an activator of TRESK (K2P 18.1, TWIK-related spinal cord K+ channel) background potassium channel. We have examined the specificity of the drug by testing several K2P channels. We have investigated the mechanism of cloxyquin-mediated TRESK activation, focusing on the differences between the physiologically relevant regulatory states of the channel. EXPERIMENTAL APPROACH: Potassium currents were measured by two-electrode voltage clamp in Xenopus oocytes and by whole-cell patch clamp in mouse dorsal root ganglion (DRG) neurons. KEY RESULTS: Cloxyquin (100 µM) activated mouse and human TRESK 4.4 ± 0.3 (n = 28) and 3.9 ± 0.3-fold (n = 8), respectively. The drug selectively targeted TRESK in the K2P channel family and exerted state-dependent effects. TRESK was potently activated by cloxyquin in the resting state. However, after robust activation of the current by the calcium signal, evoked by stimulation of Gq-coupled receptors, the compound did not influence mouse TRESK and only slightly affected the human channel. The constitutively active mutant channels, mimicking the dephosphorylated state (S276A) or containing altered channel pore (F156A and F364A), were not further stimulated by cloxyquin. In a subpopulation of isolated DRG neurons, cloxyquin substantially activated the background potassium current. CONCLUSIONS AND IMPLICATIONS: Cloxyquin activates TRESK by a Ca2+ /calcineurin-independent mechanism. The drug is specific for TRESK within the K2P channel family and useful for studying TRESK currents in native cells. The state-dependent pharmacological profile of this channel should be considered in the development of therapeutics for migraine and other nociceptive disorders.
BACKGROUND AND PURPOSE:Cloxyquin (5-cloroquinolin-8-ol) has been described as an activator of TRESK (K2P 18.1, TWIK-related spinal cord K+ channel) background potassium channel. We have examined the specificity of the drug by testing several K2P channels. We have investigated the mechanism of cloxyquin-mediated TRESK activation, focusing on the differences between the physiologically relevant regulatory states of the channel. EXPERIMENTAL APPROACH: Potassium currents were measured by two-electrode voltage clamp in Xenopus oocytes and by whole-cell patch clamp in mouse dorsal root ganglion (DRG) neurons. KEY RESULTS:Cloxyquin (100 µM) activated mouse and humanTRESK 4.4 ± 0.3 (n = 28) and 3.9 ± 0.3-fold (n = 8), respectively. The drug selectively targeted TRESK in the K2P channel family and exerted state-dependent effects. TRESK was potently activated by cloxyquin in the resting state. However, after robust activation of the current by the calcium signal, evoked by stimulation of Gq-coupled receptors, the compound did not influence mouseTRESK and only slightly affected the human channel. The constitutively active mutant channels, mimicking the dephosphorylated state (S276A) or containing altered channel pore (F156A and F364A), were not further stimulated by cloxyquin. In a subpopulation of isolated DRG neurons, cloxyquin substantially activated the background potassium current. CONCLUSIONS AND IMPLICATIONS: Cloxyquin activates TRESK by a Ca2+ /calcineurin-independent mechanism. The drug is specific for TRESK within the K2P channel family and useful for studying TRESK currents in native cells. The state-dependent pharmacological profile of this channel should be considered in the development of therapeutics for migraine and other nociceptive disorders.
Authors: Diana M Bautista; Yaron M Sigal; Aaron D Milstein; Jennifer L Garrison; Julie A Zorn; Pamela R Tsuruda; Roger A Nicoll; David Julius Journal: Nat Neurosci Date: 2008-06-22 Impact factor: 24.884
Authors: Paul D Wright; Gregory Weir; Jamie Cartland; David Tickle; Catherine Kettleborough; M Zameel Cader; Jeff Jerman Journal: Biochem Biophys Res Commun Date: 2013-11-15 Impact factor: 3.575
Authors: Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies Journal: Nucleic Acids Res Date: 2015-10-12 Impact factor: 16.971
Authors: Philippa Pettingill; Greg A Weir; Tina Wei; Yukyee Wu; Grace Flower; Tatjana Lalic; Adam Handel; Galbha Duggal; Satyan Chintawar; Jonathan Cheung; Kanisa Arunasalam; Elizabeth Couper; Larisa M Haupt; Lyn R Griffiths; Andrew Bassett; Sally A Cowley; M Zameel Cader Journal: Brain Date: 2019-12-01 Impact factor: 13.501
Authors: Tobias Ruck; Stefanie Bock; Steffen Pfeuffer; Christina B Schroeter; Derya Cengiz; Paul Marciniak; Maren Lindner; Alexander Herrmann; Marie Liebmann; Stjepana Kovac; Lukas Gola; Leoni Rolfes; Marc Pawlitzki; Nils Opel; Tim Hahn; Udo Dannlowski; Thomas Pap; Felix Luessi; Julian A Schreiber; Bernhard Wünsch; Tanja Kuhlmann; Guiscard Seebohm; Björn Tackenberg; Patricia Seja; Frank Döring; Erhard Wischmeyer; Achmet Imam Chasan; Johannes Roth; Luisa Klotz; Gerd Meyer Zu Hörste; Heinz Wiendl; Tobias Marschall; Stefan Floess; Jochen Huehn; Thomas Budde; Tobias Bopp; Stefan Bittner; Sven G Meuth Journal: Cell Res Date: 2021-10-26 Impact factor: 25.617